Eagle Ridge Investment Management grew its holdings in Johnson & Johnson (NYSE:JNJ) by 100.9% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 26,594 shares of the company’s stock after acquiring an additional 13,357 shares during the quarter. Eagle Ridge Investment Management’s holdings in Johnson & Johnson were worth $1,758,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. OLD Point Trust & Financial Services N A boosted its holdings in Johnson & Johnson by 2.2% in the second quarter. OLD Point Trust & Financial Services N A now owns 61,326 shares of the company’s stock worth $8,113,000 after acquiring an additional 1,321 shares in the last quarter. Lynch & Associates IN boosted its holdings in Johnson & Johnson by 0.9% in the second quarter. Lynch & Associates IN now owns 93,710 shares of the company’s stock worth $12,397,000 after acquiring an additional 841 shares in the last quarter. Oakbrook Investments LLC boosted its holdings in Johnson & Johnson by 7.4% in the second quarter. Oakbrook Investments LLC now owns 136,124 shares of the company’s stock worth $18,008,000 after acquiring an additional 9,375 shares in the last quarter. Trexquant Investment LP acquired a new stake in shares of Johnson & Johnson during the first quarter worth about $1,731,000. Finally, Janney Montgomery Scott LLC lifted its holdings in shares of Johnson & Johnson by 0.5% during the second quarter. Janney Montgomery Scott LLC now owns 771,868 shares of the company’s stock worth $102,110,000 after purchasing an additional 3,533 shares during the period. 65.93% of the stock is owned by institutional investors and hedge funds.

A number of equities research analysts recently commented on JNJ shares. Cowen and Company reaffirmed an “outperform” rating and set a $155.00 target price (up previously from $147.00) on shares of Johnson & Johnson in a report on Wednesday, October 18th. UBS AG reaffirmed a “buy” rating and set a $148.00 target price on shares of Johnson & Johnson in a report on Thursday, August 31st. Jefferies Group LLC lifted their target price on Johnson & Johnson from $157.00 to $160.00 and gave the stock a “buy” rating in a report on Monday, October 16th. Zacks Investment Research raised Johnson & Johnson from a “sell” rating to a “hold” rating in a report on Wednesday, October 4th. Finally, Credit Suisse Group set a $154.00 target price on Johnson & Johnson and gave the stock an “outperform” rating in a report on Thursday, October 19th. Four analysts have rated the stock with a sell rating, eight have assigned a hold rating and eleven have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $143.70.

WARNING: This article was first posted by Watch List News and is the property of of Watch List News. If you are viewing this article on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this article can be accessed at https://www.watchlistnews.com/johnson-johnson-jnj-holdings-raised-by-eagle-ridge-investment-management/1699199.html.

Shares of Johnson & Johnson (NYSE:JNJ) opened at $139.56 on Monday. The company has a market capitalization of $374,930.72, a P/E ratio of 19.55, a PEG ratio of 2.84 and a beta of 0.82. Johnson & Johnson has a 12-month low of $109.32 and a 12-month high of $144.35. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.32 and a quick ratio of 1.02.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, October 17th. The company reported $1.90 EPS for the quarter, beating the Zacks’ consensus estimate of $1.80 by $0.10. The business had revenue of $19.65 billion during the quarter, compared to analysts’ expectations of $19.29 billion. Johnson & Johnson had a return on equity of 27.38% and a net margin of 21.28%. The business’s revenue was up 10.3% compared to the same quarter last year. During the same period in the previous year, the business earned $1.68 earnings per share. sell-side analysts anticipate that Johnson & Johnson will post 7.28 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 12th. Stockholders of record on Tuesday, November 28th will be given a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.41%. The ex-dividend date is Monday, November 27th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 58.33%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with Analyst Ratings Network's FREE daily email newsletter.